Cell-type-specific, aptamer-functionalized agents for targeted disease therapy

Molecular Therapy Nucleic Acids

Volumn 3, Issue , 2014, Pages

  Zhou, Jiehua ^a   Rossi, John J ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

aptamer; cell type specific delivery; RNAi; SELEX; targeted therapy

Indexed keywords

ANTIINFECTIVE AGENT; APTAMER; DENDRIMER; GOLD NANOPARTICLE; LIPOSOME; MEMBRANE PROTEIN; NANOMATERIAL; OLIGONUCLEOTIDE; RNA; SHORT HAIRPIN RNA; SINGLE WALLED NANOTUBE; SMALL INTERFERING RNA; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; ANTINEOPLASTIC AGENT; DNA; MICRORNA; NANOCARRIER; POLYMER; QUANTUM DOT;

CELL TYPE; CONJUGATION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; HUMAN; IN VIVO STUDY; MICELLE; MOLECULARLY TARGETED THERAPY; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; ARTICLE; CELL SELECTION; CELL SPECIFICITY; CELLS BY BODY ANATOMY; CHEMICAL BOND; COMBINATORIAL CHEMISTRY; INTERCALATION COMPLEX; LIPOSOMAL DELIVERY; NANOPHARMACEUTICS; PROTEIN PURIFICATION; RNA SPLICING; TARGET CELL; TARGET ORGAN;

EID: 84902825431     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2014.21     Document Type: Review

References (128)

1. Joensuu, H (2008). Systemic chemotherapy for cancer: from weapon to treatment. Lancet Oncol 9: 304. (Pubitemid 351722950)
2. Harrison, LB, Chadha, M, Hill, RJ, Hu, K and Shasha, D (2002). Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist 7: 492-508. (Pubitemid 36008998)
3. Shapira, S, Lisiansky, V, Arber, N and Kraus, S (2010). Targeted immunotherapy for colorectal cancer: monoclonal antibodies and immunotoxins. Expert Opin Investig Drugs 19 (suppl. 1): S67-S77.
4. Whitehead, KA, Langer, R and Anderson, DG (2009). Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 8: 129-138.
5. Langer, R (1998). Drug delivery and targeting. Nature 392 (suppl. 6679): 5-10. (Pubitemid 28215187)
6. Schrama, D, Reisfeld, RA and Becker, JC (2006). Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 5: 147-159.
7. Zhou, J and Rossi, JJ (2011). Cell-specific aptamer-mediated targeted drug delivery. Oligonucleotides 21: 1-10.
8. Senter, PD, and Springer, CJ (2001). Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates. Adv Drug Deliv Rev 53: 247-264. (Pubitemid 34024909)
9. Ercan, MT and Caglar, M (2000). Therapeutic radiopharmaceuticals. Curr Pharm Des 6: 1085-1121. (Pubitemid 30460595)
10. Allen, TM (2002). Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2: 750-763. (Pubitemid 37328910)
11. Robertson, DL and Joyce, GF (1990). Selection in vitro of an RNA enzyme that specifically cleaves single-stranded DNA. Nature 344: 467-468.
12. Tuerk, C and Gold, L (1990). Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249: 505-510.
13. Ellington, AD and Szostak, JW (1990). In vitro selection of RNA molecules that bind specific ligands. Nature 346: 818-822.
14. Tan, W, Wang, H, Chen, Y, Zhang, X, Zhu, H, Yang C et al. (2011). Molecular aptamers for drug delivery. Trends Biotechnol 29: 634-640.
15. Mayer, G (2009). The chemical biology of aptamers. Angew Chem Int Ed Engl 48: 2672-2689.
16. Blank, M and Blind, M (2005). Aptamers as tools for target validation. Curr Opin Chem Biol 9: 336-342. (Pubitemid 41019677)
17. Sundaram, P, Kurniawan, H, Byrne, ME and Wower, J (2013). Therapeutic RNA aptamers in clinical trials. Eur J Pharm Sci 48: 259-271.
18. Reinemann, C and Strehlitz, B (2014). Aptamer-modified nanoparticles and their use in cancer diagnostics and treatment. Swiss Med Wkly 144: w13908.
19. Bompiani, KM, Woodruff, RS, Becker, RC, Nimjee, SM and Sullenger, BA (2012). Antidote control of aptamer therapeutics: the road to a safer class of drug agents. Curr Pharm Biotechnol 13: 1924-1934.
20. Younas, N, Wu, CM, Shapiro, R, McCauley, J, Johnston, J, Tan, H et al. (2010). HMG-CoA reductase inhibitors in kidney transplant recipients receiving tacrolimus: statins not associated with improved patient or graft survival. BMC Nephrol 11: 5.
21. Kulbachinskiy, AV (2007). Methods for selection of aptamers to protein targets. Biochemistry (Mosc) 72: 1505-1518.
22. Guo, KT, Paul, A, Schichor, C, Ziemer, G and Wendel, HP (2008). CELL-SELEX: Novel perspectives of aptamer-based therapeutics. Int J Mol Sci 9: 668-678. (Pubitemid 351631122)
23. Chen ZW, Hsuan SL, Liao JW, Chen TH, Wu CM, Lee WC et al. (2010). Mutations in the Salmonella enterica serovar Choleraesuis cAMP-receptor protein gene lead to functional defects in the SPI-1 Type III secretion system. Vet Res 41: 5.
24. Berezovski M, Drabovich A, Krylova SM, Musheev M, Okhonin V, Petrov A et al. (2005). Nonequilibrium capillary electrophoresis of equilibrium mixtures: a universal tool for development of aptamers. J Am Chem Soc 127: 3165-3171. (Pubitemid 40349896)
25. Berezovski, M, Musheev, M, Drabovich, A and Krylov, SN (2006). Non-SELEX selection of aptamers. J Am Chem Soc 128: 1410-1411. (Pubitemid 43214828)
26. Mallikaratchy, P, Stahelin, RV, Cao, Z, Cho, W, and Tan, W (2006). Selection of DNA ligands for protein kinase C-delta. Chem Commun (Camb): 3229-3231. (Pubitemid 44126575)
27. Farokhzad OC, Khademhosseini A, Jon S, Hermmann A, Cheng J, Chin C et al. (2005). Microfluidic system for studying the interaction of nanoparticles and microparticles with cells. Anal Chem 77: 5453-5459. (Pubitemid 41266036)
28. Lupold, SE, Hicke, BJ, Lin, Y and Coffey, DS (2002). Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostatespecific membrane antigen. Cancer Res 62: 4029-4033. (Pubitemid 34791070)
29. Kraus, E, James, W and Barclay, AN (1998). Cutting edge: novel RNA ligands able to bind CD4 antigen and inhibit CD4+ T lymphocyte function. J Immunol 160: 5209-5212. (Pubitemid 28267804)
30. Zhou, J, Swiderski, P, Li, H, Zhang, J, Neff, CP, Akkina, R et al. (2009). Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res 37: 3094-3109.
31. Zhou, J, Tiemann, K, Chomchan, P, Alluin, J, Swiderski, P, Burnett, J et al. (2013). Dual functional BAFF receptor aptamers inhibit ligand-induced proliferation and deliver siRNAs to NHL cells. Nucleic Acids Res 41: 4266-4283.
32. Li, N, Larson, T, Nguyen, HH, Sokolov, KV and Ellington, AD (2010). Directed evolution of gold nanoparticle delivery to cells. Chem Commun (Camb) 46: 392-394.
33. Cerchia, L and de Franciscis, V (2010). Targeting cancer cells with nucleic acid aptamers. Trends Biotechnol 28: 517-525.
34. Cerchia, L, Ducongé F, Pestourie, C, Boulay, J, Aissouni, Y, Gombert, K et al. (2005). Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase. PLoS Biol 3: e123.
35. Pestourie C, Cerchia L, Gombert K, Aissouni Y, Boulay J, De Franciscis V et al. (2006). Comparison of different strategies to select aptamers against a transmembrane protein target. Oligonucleotides 16: 323-335. (Pubitemid 46043154)
36. Fang, X and Tan, W (2010). Aptamers generated from cell-SELEX for molecular medicine: a chemical biology approach. Acc Chem Res. 43: 48-57.
37. Shangguan, D, Li, Y, Tang, Z, Cao, ZC, Chen, HW, Mallikaratchy, P et al. (2006). Aptamers evolved from live cells as effective molecular probes for cancer study. Proc Natl Acad Sci USA 103: 11838-11843. (Pubitemid 44215773)
38. Shangguan, D, Cao, ZC, Li, Y and Tan, W (2007). Aptamers evolved from cultured cancer cells reveal molecular differences of cancer cells in patient samples. Clin Chem 53: 1153-1155. (Pubitemid 46867534)
39. Thiel, KW, Hernandez, LI, Dassie, JP, Thiel, WH, Liu, X, Stockdale, KR et al. (2012). Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers. Nucleic Acids Res 40: 6319-6337.
40. Ohuchi, S (2012). Cell-SELEX Technology. Biores Open Access 1: 265-272.
41. Mi J, Liu Y, Rabbani ZN, Yang, Z, Urban, JH, Sullenger, BA et al. (2010). In vivo selection of tumor-targeting RNA motifs. Nat Chem Biol 6: 22-24.
42. Cheng, C, Chen, YH, Lennox, KA, Behlke, MA and Davidson, BL (2013). In vivo SELEX for identification of brain-penetrating aptamers. Mol Ther Nucleic Acids 2: e67.
43. Keefe, AD and Cload, ST (2008). SELEX with modified nucleotides. Curr Opin Chem Biol 12: 448-456.
44. Ray, P, Viles, KD, Soule, EE and Woodruff, RS (2013). Application of aptamers for targeted therapeutics. Arch Immunol Ther Exp 61: 255-271.
45. Xing, H, Wong, NY, Xiang, Y and Lu, Y (2012). DNA aptamer functionalized nanomaterials for intracellular analysis, cancer cell imaging and drug delivery. Curr Opin Chem Biol 16: 429-435.
46. Keefe, AD, Pai, S and Ellington, A (2010). Aptamers as therapeutics. Nat Rev Drug Discov 9: 537-550.
47. Shu, Y, Pi, F, Sharma, A, Rajabi, M, Haque, F, Shu, D et al. (2014). Stable RNA nanoparticles as potential new generation drugs for cancer therapy. Adv Drug Deliv Rev 66C: 74-89.
48. Zhou, J and Rossi, JJ (2009). The therapeutic potential of cell-internalizing aptamers. Curr Top Med Chem 9: 1144-1157.
49. Bourrinet, P, Bengele, HH, Bonnemain, B, Dencausse, A, Idee, JM, Jacobs, PM et al. (2006). Preclinical safety and pharmacokinetic profile of ferumoxtran-10, an ultrasmall superparamagnetic iron oxide magnetic resonance contrast agent. Invest Radiol 41: 313-324. (Pubitemid 44406193)
50. Kim, JS, Shin, DC, Woo, MY, Kwon, MH, Kim, K and Park, S (2012). T Cell immunoglobulin mucin domain (TIM)-3 promoter activity in a human mast cell line. Immune Netw 12: 207-212.
51. Piao, T, Comita, LS, Jin, G and Kim, JH (2013). Density dependence across multiple life stages in a temperate old-growth forest of northeast China. Oecologia 172: 207-217.
52. Fire, A, Xu, S, Montgomery, MK, Kostas, SA, Driver, SE and Mello, CC (1998). Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391: 806-811. (Pubitemid 28099681)
53. Davidson, BL and McCray, PB Jr (2011). Current prospects for RNA interference-based therapies. Nat Rev Genet 12: 329-340.
54. Lares, MR, Rossi, JJ and Ouellet, DL (2010). RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol 28: 570-579.
55. de Fougerolles, A, Vornlocher, HP, Maraganore, J and Lieberman, J (2007). Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 6: 443-453. (Pubitemid 47064567)
56. Castanotto, D and Rossi, JJ (2009). The promises and pitfalls of RNA-interference-based therapeutics. Nature 457: 426-433.
57. McNamara, JO 2nd, Andrechek, ER, Wang, Y, Viles, KD, Rempel, RE, Gilboa, E et al. (2006). Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 24: 1005-1015. (Pubitemid 44215395)
58. Dassie, JP, Liu, XY, Thomas, GS, Whitaker, RM, Thiel, KW, Stockdale, KR et al. (2009). Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol 27: 839-849.
59. Pastor, F, Kolonias, D, Giangrande, PH and Gilboa, E (2010). Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay. Nature 465: 227-230.
60. Zhou, J, Li, H, Li, S, Zaia, J and Rossi, JJ (2008). Novel dual inhibitory function aptamersiRNA delivery system for HIV-1 therapy. Mol Ther 16: 1481-1489.
61. Neff, CP, Zhou, J, Remling, L, Kuruvilla, J, Zhang, J, Li, H et al. (2011). An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice. Sci Transl Med 3: 66ra66.
62. Wheeler, LA, Trifonova, R, Vrbanac, V, Basar, E, McKernan, S, Xu, Z et al. (2011). Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras. J Clin Invest 121: 2401-2412.
63. Ni, X, Zhang, Y, Ribas, J, Chowdhury, WH, Castanares, M, Zhang, Z et al. (2011). Prostatetargeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts. J Clin Invest. 121: 2383-2390.
64. Wullner, U, Neef, I, Eller, A, Kleines, M, Tur, MK and Barth, S (2008). Cell-specific induction of apoptosis by rationally designed bivalent aptamer-siRNA transcripts silencing eukaryotic elongation factor 2. Curr Cancer Drug Targets 8: 554-565.
65. Zhu, Q, Shibata, T, Kabashima, T and Kai, M (2012). Inhibition of HIV-1 protease expression in T cells owing to DNA aptamer-mediated specific delivery of siRNA. Eur J Med Chem 56: 396-399.
66. Mu, C, Dave, N, Hu, J, Desai, P, Pauletti, G, Bai, S et al. (2013). Solubilization of flurbiprofen into aptamer-modified PEG-PLA micelles for targeted delivery to brain-derived endothelial cells in vitro. J Microencapsul 30: 701-708.
67. Sun, X, Huang, L, Zhang, M, Sun, S and Wu, Y (2010). Insulin like growth factor-1 prevents 1-mentyl-4-phenylphyridinium-induced apoptosis in PC12 cells through activation of glycogen synthase kinase-3beta. Toxicology 271: 5-12.
68. Altschuler, Y, Kinlough, CL, Poland, PA, Bruns, JB, Apodaca, G, Weisz, OA et al. (2000). Clathrin-mediated endocytosis of MUC1 is modulated by its glycosylation state. Mol Biol Cell 11: 819-831. (Pubitemid 30159304)
69. Gendler, SJ (2001). MUC1, the renaissance molecule. J Mammary Gland Biol Neoplasia 6: 339-353.
70. Xu, W, Siddiqui, IA, Nihal, M, Pilla, S, Rosenthal, K, Mukhtar, H et al. (2013). Aptamerconjugated and doxorubicin-loaded unimolecular micelles for targeted therapy of prostate cancer. Biomaterials 34: 5244-5253.
71. Kotula, JW, Pratico, ED, Ming, X, Nakagawa, O, Juliano, RL and Sullenger, BA (2012). Aptamer-mediated delivery of splice-switching oligonucleotides to the nuclei of cancer cells. Nucleic Acid Ther 22: 187-195.
72. Bates, PJ, Laber, DA, Miller, DM, Thomas, SD and Trent, JO (2009). Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp Mol Pathol 86: 151-164.
73. Bates, PJ, Kahlon, JB, Thomas, SD, Trent, JO and Miller, DM (1999). Antiproliferative activity of G-rich oligonucleotides correlates with protein binding. J Biol Chem 274: 26369-26377.
74. Chu, TC, Twu, KY, Ellington, AD and Levy, M (2006). Aptamer mediated siRNA delivery. Nucleic Acids Res 34: e73.
75. Zhou, J, Neff, CP, Swiderski, P, Li, H, Smith, DD, Aboellail, T et al. (2013). Functional in vivo delivery of multiplexed anti-HIV-1 siRNAs via a chemically synthesized aptamer with a sticky bridge. Mol Ther 21: 192-200.
76. Wu, J, Song, C, Jiang, C, Shen, X, Qiao, Q and Hu, Y (2013). Nucleolin targeting AS1411 modified protein nanoparticle for antitumor drugs delivery. Mol Pharm 10: 3555-3563.
77. Gilboa, E, McNamara, J, 2nd and Pastor, F (2013). Use of oligonucleotide aptamer ligands to modulate the function of immune receptors. Clin Cancer Res 19: 1054-1062.
78. Pastor, F, Kolonias, D, McNamara, JO, 2nd and Gilboa, E (2011). Targeting 4-1BB costimulation to disseminated tumor lesions with bi-specific oligonucleotide aptamers. Mol Ther 19: 1878-1886.
79. McNamara, JO, Kolonias, D, Pastor, F, Mittler, RS, Chen, L, Giangrande, PH et al. (2008). Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice. J Clin Invest 118: 376-386.
80. Huang, YF, Shangguan, D, Liu, H, Phillips, JA, Zhang, X, Chen, Y et al. (2009). Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells. Chembiochem 10: 862-868.
81. Xiao, Z, Shangguan, D, Cao, Z, Fang, X and Tan, W (2008). Cell-specific internalization study of an aptamer from whole cell selection. Chemistry 14: 1769-1775.
82. Gao, H, Qian, J, Yang, Z, Pang, Z, Xi, Z, Cao, S et al. (2012). Whole-cell SELEX aptamerfunctionalised poly(ethyleneglycol)-poly(epsilon- caprolactone) nanoparticles for enhanced targeted glioblastoma therapy. Biomaterials 33: 6264-6272.
83. Chu, TC, Marks, JW 3rd, Lavery, LA, Faulkner, S, Rosenblum, MG, Ellington, AD et al. (2006). Aptamer:toxin conjugates that specifically target prostate tumor cells. Cancer Res 66: 5989-5992.
84. Chen, CH, Dellamaggiore, KR, Ouellette, CP, Sedano, CD, Lizadjohry, M, Chernis, GA et al. (2008). Aptamer-based endocytosis of a lysosomal enzyme. Proc Natl Acad Sci USA 105: 15908-15913.
85. Bagalkot, V, Farokhzad, OC, Langer, R and Jon, S (2006). An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew Chem Int Ed Engl 45: 8149-8152. (Pubitemid 44974149)
86. Hu, Y, Duan, J, Zhan, Q, Wang, F, Lu, X and Yang, XD (2012). Novel MUC1 aptamer selectively delivers cytotoxic agent to cancer cells in vitro. PLoS One 7: e31970.
87. Liu, Z, Duan, JH, Song, YM, Ma, J, Wang, FD, Lu, X et al. (2012). Novel HER2 aptamer selectively delivers cytotoxic drug to HER2-positive breast cancer cells in vitro. J Transl Med 10: 148.
88. Tan, L, Gee Neoh, K, Kang, ET, Choe, WS and Su, X (2012). Designer tridentate mucin 1 aptamer for targeted drug delivery. J Pharm Sci 101: 1672-1677.
89. Shieh, YA, Yang, SJ, Wei, MF and Shieh, MJ (2010). Aptamer-based tumor-targeted drug delivery for photodynamic therapy. ACS Nano 4: 1433-1442.
90. Rana, S, Bajaj, A, Mout, R and Rotello, VM (2012). Monolayer coated gold nanoparticles for delivery applications. Adv Drug Deliv Rev 64: 200-216.
91. Luo, YL, Shiao, YS and Huang, YF (2011). Release of photoactivatable drugs from plasmonic nanoparticles for targeted cancer therapy. ACS Nano 5: 7796-7804.
92. Wang, J, Zhu, G, You, M, Song, E, Shukoor, MI, Zhang, K et al. (2012). Assembly of aptamer switch probes and photosensitizer on gold nanorods for targeted photothermal and photodynamic cancer therapy. ACS Nano 6: 5070-5077.
93. Zhao, N, You, J, Zeng, Z, Li, C and Zu, Y (2013). An ultra pH-sensitive and aptamerequipped nanoscale drug-delivery system for selective killing of tumor cells. Small 9: 3477-3484.
94. Wang, AZ, Bagalkot, V, Vasilliou, CC, Gu, F, Alexis, F, Zhang, L et al. (2008). Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy. Chem Med Chem 3: 1311-1315.
95. Meng, L, Zhang, X, Lu, Q, Fei, Z and Dyson, PJ (2012). Single walled carbon nanotubes as drug delivery vehicles: targeting doxorubicin to tumors. Biomaterials 33: 1689-1698.
96. Taghdisi, SM, Lavaee, P, Ramezani, M and Abnous, K (2011). Reversible targeting and controlled release delivery of daunorubicin to cancer cells by aptamer-wrapped carbon nanotubes. Eur J Pharm Biopharm 77: 200-206.
97. Zhu, Z, Tang, Z, Phillips, JA, Yang, R, Wang, H and Tan, W (2008). Regulation of singlet oxygen generation using single-walled carbon nanotubes. J Am Chem Soc 130: 10856-10857.
98. Yang, X, Liu, X, Liu, Z, Pu, F, Ren, J and Qu, X (2012). Near-infrared light-triggered, targeted drug delivery to cancer cells by aptamer gated nanovehicles. Adv Mater 24: 2890-2895.
99. Kim, JK, Choi, KJ, Lee, M, Jo, MH and Kim, S (2012). Molecular imaging of a cancertargeting theragnostics probe using a nucleolin aptamer-and microRNA-221 molecular beacon-conjugated nanoparticle. Biomaterials 33: 207-217.
100. Savla, R, Taratula, O, Garbuzenko, O and Minko, T (2011). Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer. J Control Release 153: 16-22.
101. Shen, H, Sun, T and Ferrari, M (2012). Nanovector delivery of siRNA for cancer therapy. Cancer Gene Ther 19: 367-373.
102. Kang, H, O'Donoghue, MB, Liu, H and Tan, W (2010). A liposome-based nanostructure for aptamer directed delivery. Chem Commun (Camb) 46: 249-251.
103. Cao, Z, Tong, R, Mishra, A, Xu, W, Wong, GC, Cheng, J et al. (2009). Reversible cellspecific drug delivery with aptamer-functionalized liposomes. Angew Chem Int Ed Engl 48: 6494-6498.
104. Wilner, SE, Wengerter, B, Maier, K, de Lourdes Borba Magalhães, M, Del Amo, DS, Pai, S et al. (2012). An RNA alternative to human transferrin: a new tool for targeting human cells. Mol Ther Nucleic Acids 1: e21.
105. Wu, C, Chen, T, Han, D, You, M, Peng, L, Cansiz, S et al. (2013). Engineering of switchable aptamer micelle flares for molecular imaging in living cells. ACS Nano 7: 5724-5731.
106. Wu, Y, Sefah, K, Liu, H, Wang, R and Tan, W (2010). DNA aptamer-micelle as an efficient detection/delivery vehicle toward cancer cells. Proc Natl Acad Sci USA 107: 5-10.
107. Zhao, Y, Duan, S, Zeng, X, Liu, C, Davies, NM, Li, B et al. (2012). Prodrug strategy for PSMA-targeted delivery of TGX-221 to prostate cancer cells. Mol Pharm 9: 1705-1716.
108. Cohen, BA and Bergkvist, M (2013). Targeted in vitro photodynamic therapy via aptamerlabeled, porphyrin-loaded virus capsids. J Photochem Photobiol B 121: 67-74.
109. Liu, HY and Gao, X (2013). A universal protein tag for delivery of SiRNA-aptamer chimeras. Sci Rep 3: 3129.
110. Li, X, Zhao, Q and Qiu, L (2013). Smart ligand: aptamer-mediated targeted delivery of chemotherapeutic drugs and siRNA for cancer therapy. J Control Release 171: 152-162.
111. Farokhzad, OC, Jon, S, Khademhosseini, A, Tran, TN, Lavan, DA and Langer, R (2004). Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res 64: 7668-7672. (Pubitemid 39446893)
112. Farokhzad, OC, Cheng, J, Teply, BA, Sherifi, I, Jon, S, Kantoff, PW et al. (2006). Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA 103: 6315-6320.
113. Dhar, S, Gu, FX, Langer, R, Farokhzad, OC and Lippard, SJ (2008). Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci USA 105: 17356-17361.
114. Gu, F, Zhang, L, Teply, BA, Mann, N, Wang, A, Radovic-Moreno, AF et al. (2008). Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci USA 105: 2586-2591. (Pubitemid 351520557)
115. Cheng, J, Teply, BA, Sherifi, I, Sung, J, Luther, G, Gu, FX et al. (2007). Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 28: 869-876. (Pubitemid 44667020)
116. Aravind, A, Jeyamohan, P, Nair, R, Veeranarayanan, S, Nagaoka, Y, Yoshida, Y et al. (2012). AS1411 aptamer tagged PLGA-lecithin-PEG nanoparticles for tumor cell targeting and drug delivery. Biotechnol Bioeng 109: 2920-2931.
117. Zhao, N, Bagaria, HG, Wong, MS and Zu, Y (2011). A nanocomplex that is both tumor cell-selective and cancer gene-specific for anaplastic large cell lymphoma. J Nanobiotechnology 9: 2.
118. Morris, SW, Kirstein, MN, Valentine, MB, Dittmer, KG, Shapiro, DN, Saltman, DL et al. (1994). Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263: 1281-1284. (Pubitemid 24107549)
119. Yang, J, Xie, SX, Huang, Y, Ling, M, Liu, J, Ran, Y et al. (2012). Prostate-targeted biodegradable nanoparticles loaded with androgen receptor silencing constructs eradicate xenograft tumors in mice. Nanomedicine (Lond) 7: 1297-1309.
120. Bagalkot, V and Gao, X (2011). siRNA-aptamer chimeras on nanoparticles: preserving targeting functionality for effective gene silencing. ACS Nano 5: 8131-8139.
121. Boas, U and Heegaard, PM (2004). Dendrimers in drug research. Chem Soc Rev 33: 43-63. (Pubitemid 38376610)
122. Lee, IH, An, S, Yu, MK, Kwon, HK, Im, SH and Jon, S (2011). Targeted chemoimmunotherapy using drug-loaded aptamer-dendrimer bioconjugates. J Control Release 155: 435-441.
123. Wu, X, Ding, B, Gao, J, Wang, H, Fan, W, Wang, X et al. (2011). Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy. Int J Nanomedicine 6: 1747-1756.
124. Zhang, L, Radovic-Moreno, AF, Alexis, F, Gu, FX, Basto, PA, Bagalkot, V et al. (2007). Codelivery of hydrophobic and hydrophilic drugs from nanoparticle-aptamer bioconjugates. Chem Med Chem 2: 1268-1271.
125. Kim, E, Jung, Y, Choi, H, Yang, J, Suh, JS, Huh, YM et al. (2010). Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamerconjugated polyplex. Biomaterials 31: 4592-4599.
126. Ng, EW, Shima, DT, Calias, P, Cunningham, ET Jr, Guyer, DR and Adamis, AP (2006). Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 5: 123-132.
127. Tucker, CE, Chen, LS, Judkins, MB, Farmer, JA, Gill, SC and Drolet, DW (1999). Detection and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotideaptamer (NX1838) in rhesus monkeys. J Chromatogr B Biomed Sci Appl 732: 203-212. (Pubitemid 29421761)
128. Drolet, DW, Nelson, J, Tucker, CE, Zack, PM, Nixon, K, Bolin, R et al. (2000). Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharm Res 17: 1503-1510. (Pubitemid 32217559)